BRPI0711148A2 - métodos e aparelho para identificar status de doença utilizando biomarcadores - Google Patents

métodos e aparelho para identificar status de doença utilizando biomarcadores Download PDF

Info

Publication number
BRPI0711148A2
BRPI0711148A2 BRPI0711148-7A BRPI0711148A BRPI0711148A2 BR PI0711148 A2 BRPI0711148 A2 BR PI0711148A2 BR PI0711148 A BRPI0711148 A BR PI0711148A BR PI0711148 A2 BRPI0711148 A2 BR PI0711148A2
Authority
BR
Brazil
Prior art keywords
condition
data
biomarker
biomarker data
negative
Prior art date
Application number
BRPI0711148-7A
Other languages
English (en)
Portuguese (pt)
Inventor
F. Randall Grimes
Original Assignee
Provista Diagnostics, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Provista Diagnostics, Llc filed Critical Provista Diagnostics, Llc
Publication of BRPI0711148A2 publication Critical patent/BRPI0711148A2/pt

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57545—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5755—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the uterine cervix, uterine corpus or endometrium
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H70/00—ICT specially adapted for the handling or processing of medical references
    • G16H70/60—ICT specially adapted for the handling or processing of medical references relating to pathologies
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Biophysics (AREA)
  • Theoretical Computer Science (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Genetics & Genomics (AREA)
  • Primary Health Care (AREA)
  • Artificial Intelligence (AREA)
  • Software Systems (AREA)
  • Evolutionary Computation (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Gastroenterology & Hepatology (AREA)
BRPI0711148-7A 2006-05-01 2007-04-25 métodos e aparelho para identificar status de doença utilizando biomarcadores BRPI0711148A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/381.104 2006-05-01
US11/381,104 US20070255113A1 (en) 2006-05-01 2006-05-01 Methods and apparatus for identifying disease status using biomarkers
PCT/US2007/067418 WO2007130831A2 (en) 2006-05-01 2007-04-25 Methods and apparatus for identifying disease status using biomarkers

Publications (1)

Publication Number Publication Date
BRPI0711148A2 true BRPI0711148A2 (pt) 2011-08-23

Family

ID=38648787

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0711148-7A BRPI0711148A2 (pt) 2006-05-01 2007-04-25 métodos e aparelho para identificar status de doença utilizando biomarcadores

Country Status (13)

Country Link
US (5) US20070255113A1 (enExample)
EP (2) EP3318995A1 (enExample)
JP (1) JP2009535644A (enExample)
KR (1) KR20090024686A (enExample)
CN (1) CN101479599A (enExample)
AU (1) AU2007248299A1 (enExample)
BR (1) BRPI0711148A2 (enExample)
CA (1) CA2650872C (enExample)
IL (1) IL195054A0 (enExample)
MX (1) MX2008013978A (enExample)
RU (1) RU2008147223A (enExample)
WO (1) WO2007130831A2 (enExample)
ZA (1) ZA200809968B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313497A (zh) * 2018-04-27 2021-02-02 纳诺斯迪科公司 使用微流式细胞术诊断疾病的方法

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8158374B1 (en) 2006-09-05 2012-04-17 Ridge Diagnostics, Inc. Quantitative diagnostic methods using multiple parameters
US20090047694A1 (en) * 2007-08-17 2009-02-19 Shuber Anthony P Clinical Intervention Directed Diagnostic Methods
US8431367B2 (en) 2007-09-14 2013-04-30 Predictive Biosciences Corporation Detection of nucleic acids and proteins
US20090075266A1 (en) * 2007-09-14 2009-03-19 Predictive Biosciences Corporation Multiple analyte diagnostic readout
US7955822B2 (en) * 2007-09-14 2011-06-07 Predictive Biosciences Corp. Detection of nucleic acids and proteins
US20100267041A1 (en) * 2007-09-14 2010-10-21 Predictive Biosciences, Inc. Serial analysis of biomarkers for disease diagnosis
US20110245092A1 (en) * 2008-03-04 2011-10-06 John Bilello Diagnosing and monitoring depression disorders based on multiple serum biomarker panels
WO2009114627A2 (en) * 2008-03-12 2009-09-17 Ridge Diagnostics, Inc. Inflammatory biomarkers for monitoring depression disorders
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
AU2009282117B2 (en) 2008-08-11 2016-05-12 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
EP2356453A4 (en) 2008-11-18 2012-08-15 Ridge Diagnostics Inc METABOLISM SYNDROME AND HPA AXIS BIOMARKERS FOR HEAVY DEPRESSION
US8509884B2 (en) * 2009-08-28 2013-08-13 Neba Health LLC Systems and methods to identify a subgroup of ADHD at higher risk for complicating conditions
US8679474B2 (en) 2010-08-04 2014-03-25 StemBios Technologies, Inc. Somatic stem cells
US20150127378A1 (en) * 2012-02-11 2015-05-07 Yougene Corp. Systems for storing, processing and utilizing proprietary genetic information
JP6075973B2 (ja) * 2012-06-04 2017-02-08 富士通株式会社 健康状態判定装置およびその作動方法
EP2684513A1 (en) 2012-07-13 2014-01-15 Universite D'angers Method for providing reliable non-invasive diagnostic tests
JP6495174B2 (ja) 2012-12-06 2019-04-03 ステムバイオス テクノロジーズ，インコーポレイテッド Ｌｇｒ５＋体性幹細胞
EP2746769A1 (en) * 2012-12-21 2014-06-25 Stembios Technologies, Inc. Method for evaluating effect of action on subject based on stem celldynamics
EP2971054A4 (en) * 2013-03-14 2017-04-12 Otraces Inc. A method for improving disease diagnosis using measured analytes
US20140275294A1 (en) * 2013-03-15 2014-09-18 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of liver injury
CN103279655A (zh) * 2013-05-20 2013-09-04 浙江大学 一种恶性肿瘤放化疗规范符合度的评估方法
WO2014190230A1 (en) * 2013-05-23 2014-11-27 Iphenotype Llc Phenotypic integrated social search database and method
WO2014201516A2 (en) 2013-06-20 2014-12-24 Immunexpress Pty Ltd Biomarker identification
CN111540410B (zh) * 2013-12-16 2024-04-02 菲利普莫里斯生产公司 用于预测个体的吸烟状况的系统和方法
US11047010B2 (en) 2014-02-06 2021-06-29 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits thereof
CA2945165A1 (en) * 2014-04-08 2015-10-15 Metabolon, Inc. Small molecule biochemical profiling of individual subjects for disease diagnosis and health assessment
US20150294081A1 (en) 2014-04-11 2015-10-15 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US9176113B1 (en) 2014-04-11 2015-11-03 Synapdx Corporation Methods and systems for determining autism spectrum disorder risk
US10525020B2 (en) 2015-02-11 2020-01-07 Laboratory Corporation Of America Holdings Metabolic markers of attention deficit hyperactivity disorder
HK1249182A1 (zh) * 2015-05-28 2018-10-26 Immunexpress Pty Ltd 验证生物标志物测量
EP3405896A4 (en) * 2016-01-22 2019-09-25 Otraces Inc. SYSTEMS AND METHOD FOR IMPROVED DIAGNOSIS OF ILLNESSES
US11594310B1 (en) 2016-03-31 2023-02-28 OM1, Inc. Health care information system providing additional data fields in patient data
US11957897B2 (en) 2016-04-22 2024-04-16 Newton Howard Biological co-processor (BCP)
EP3532496A1 (en) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
US11257574B1 (en) 2017-03-21 2022-02-22 OM1, lnc. Information system providing explanation of models
JP7524064B2 (ja) * 2018-03-19 2024-07-29 エスアールアイ インターナショナル バイオマーカー解析のための方法およびシステム
US20190302119A1 (en) * 2018-03-27 2019-10-03 Lawrence Abraham Cancer Diagnostic Metastasis Panel
US11967428B1 (en) * 2018-04-17 2024-04-23 OM1, Inc. Applying predictive models to data representing a history of events
LU100835B1 (en) * 2018-06-13 2019-12-13 Univ Muenster Westfaelische Wilhelms Novel biomarkers for recurrent tonsillitis
US11862346B1 (en) 2018-12-22 2024-01-02 OM1, Inc. Identification of patient sub-cohorts and corresponding quantitative definitions of subtypes as a classification system for medical conditions
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
US20200395097A1 (en) * 2019-05-30 2020-12-17 Tempus Labs, Inc. Pan-cancer model to predict the pd-l1 status of a cancer cell sample using rna expression data and other patient data
TWI740647B (zh) * 2020-09-15 2021-09-21 宏碁股份有限公司 疾病分類方法及疾病分類裝置
US20220223231A1 (en) * 2021-01-14 2022-07-14 The Board Of Trustees Of The Leland Stanford Junior University Systems and Methods for Improved Prognostics in Medical Imaging
KR102671925B1 (ko) * 2022-03-03 2024-06-03 인제대학교 산학협력단 파킨슨병 진단 방법 및 그 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197532B1 (en) * 1998-01-22 2001-03-06 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Diagnosis and detection of breast cancer and other cancers
US6882990B1 (en) * 1999-05-01 2005-04-19 Biowulf Technologies, Llc Methods of identifying biological patterns using multiple data sets
EP1037158A3 (en) * 1999-03-15 2003-06-18 Whitehead Institute For Biomedical Research Methods and apparatus for analyzing gene expression data
US6647341B1 (en) * 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
US6750013B2 (en) * 1999-12-02 2004-06-15 Protein Design Labs, Inc. Methods for detection and diagnosing of breast cancer
EP1417297A4 (en) * 2001-07-13 2007-08-22 Whitehead Biomedical Inst LEUKEMOGENIC TRANSCRIPTION FACTORS
US20030225526A1 (en) * 2001-11-14 2003-12-04 Golub Todd R. Molecular cancer diagnosis using tumor gene expression signature
US6949342B2 (en) * 2001-12-21 2005-09-27 Whitehead Institute For Biomedical Research Prostate cancer diagnosis and outcome prediction by expression analysis
EP1495419A2 (en) * 2002-04-01 2005-01-12 Phase-1 Molecular Toxicology Inc. Liver necrosis predictive genes
US20050176057A1 (en) 2003-09-26 2005-08-11 Troy Bremer Diagnostic markers of mood disorders and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112313497A (zh) * 2018-04-27 2021-02-02 纳诺斯迪科公司 使用微流式细胞术诊断疾病的方法

Also Published As

Publication number Publication date
CA2650872C (en) 2018-04-24
RU2008147223A (ru) 2010-06-10
WO2007130831A3 (en) 2008-10-30
WO2007130831A2 (en) 2007-11-15
JP2009535644A (ja) 2009-10-01
ZA200809968B (en) 2009-08-26
KR20090024686A (ko) 2009-03-09
US20110077931A1 (en) 2011-03-31
EP2016405A2 (en) 2009-01-21
MX2008013978A (es) 2009-02-19
IL195054A0 (en) 2009-08-03
CA2650872A1 (en) 2007-11-15
US20210041440A1 (en) 2021-02-11
EP3318995A1 (en) 2018-05-09
US20070255113A1 (en) 2007-11-01
AU2007248299A1 (en) 2007-11-15
US20070254369A1 (en) 2007-11-01
CN101479599A (zh) 2009-07-08
EP2016405A4 (en) 2012-10-03
US20130060549A1 (en) 2013-03-07
EP2016405B1 (en) 2017-09-27

Similar Documents

Publication Publication Date Title
US20210041440A1 (en) Methods and apparatus for identifying disease status using biomarkers
Bradley et al. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer
Mounce et al. Cancer incidence following a high-normal platelet count: cohort study using electronic healthcare records from English primary care
Wu et al. Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients
Tong et al. Fasting plasma glucose in the first trimester is related to gestational diabetes mellitus and adverse pregnancy outcomes
Schaff et al. Novel centrifugal technology for measuring sperm concentration in the home
CN105229471B (zh) 用于基于生物化学标记分析确定先兆子痫风险的系统和方法
Fernández‐Sueiro et al. Validity of the bath ankylosing spondylitis disease activity index for the evaluation of disease activity in axial psoriatic arthritis
Guo et al. Sources of heterogeneities in estimating the prevalence of endometriosis in infertile and previously fertile women
Yin et al. Identifying cancer cachexia in patients without weight loss information: machine learning approaches to address a real-world challenge
Wynants et al. Screening for data clustering in multicenter studies: the residual intraclass correlation
Schaefer et al. Prediction of gestational diabetes mellitus in the Born in Guangzhou Cohort Study, China
Ikeda et al. Preoperative sarcopenia and malnutrition are correlated with poor long-term survival after endovascular abdominal aortic aneurysm repair
Kityo et al. Association of cardiometabolic factors and insulin resistance surrogates with mortality in participants from the Korean Genome and Epidemiology Study
Yucel et al. The effect of lactate/albumin ratio on mortality in patients with sepsis
Bartoszko et al. Development of a repeated-measures predictive model and clinical risk score for mortality in ventilated COVID-19 patients
He et al. Prediction models for postoperative pneumonia in elderly hip fracture patients: a systematic review and critical appraisal
WO2018174876A1 (en) Methods and compositions for providing a preeclampsia assessment with metabolites
Ma et al. Value of SLE-DAS in assessing disease activity in patients with systemic lupus erythematosus: a single-centre retrospective study
Rafiei Sorouri et al. Red cell distribution width and mean platelet volume detection in patients with endometrial cancer and endometrial hyperplasia
Matsuo et al. Association between sentinel lymph node biopsy and micrometastasis in endometrial cancer
Vrbanic et al. Intracranial haemorrhage and falls: cause or effect?
Harbottle et al. A novel 8.7-kb mitochondrial genome deletion accurately detects endometriosis in the plasma of symptomatic women
Christensen et al. Arterial blood gas derangement and level of comorbidity are not predictors of long-term mortality of COPD patients treated with mechanical ventilation
Patel et al. Validation of PROMIS score as a measure of postoperative success following decompressive surgery for Chiari I malformation

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A E 5A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: NAO APRESENTADA A GUIA DE CUMPRIMENTO DE EXIGENCIA. REFERENTE AS 4A E 5A ANUIDADES.